RAPT RAPT Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RAPT

Price (delayed)

$8.21

Market cap

$285.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.05

Enterprise value

$245.12M

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. ...

Highlights
The debt is down by 23% year-on-year and by 7% since the previous quarter
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rapt.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RAPT
Market
Shares outstanding
34.8M
Market cap
$285.69M
Enterprise value
$245.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$116.8M
EBITDA
-$113.25M
Free cash flow
-$98.17M
Per share
EPS
-$3.05
Free cash flow per share
-$2.56
Book value per share
$4.27
Revenue per share
$0
TBVPS
$4.52
Balance sheet
Total assets
$173.33M
Total liabilities
$26.29M
Debt
$6.91M
Equity
$147.04M
Working capital
$139.95M
Liquidity
Debt to equity
0.05
Current ratio
7.41
Quick ratio
7.28
Net debt/EBITDA
0.36
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.5%
Return on equity
-63.1%
Return on invested capital
-78.5%
Return on capital employed
-77.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RAPT stock price

How has the RAPT Therapeutics stock price performed over time
Intraday
0.98%
1 week
1.36%
1 month
-1.79%
1 year
-56.28%
YTD
-66.96%
QTD
-8.57%

Financial performance

How have RAPT Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$127.06M
Net income
-$116.8M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
RAPT's operating income is down by 48% YoY and by 7% QoQ
The net income has contracted by 39% YoY and by 7% from the previous quarter

Growth

What is RAPT Therapeutics's growth rate over time

Valuation

What is RAPT Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RAPT's EPS is down by 18% year-on-year and by 6% since the previous quarter
The P/B is 59% lower than the 5-year quarterly average of 4.6 and 50% lower than the last 4 quarters average of 3.8
RAPT's equity is down by 40% year-on-year and by 15% since the previous quarter
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is RAPT Therapeutics business performance
The ROIC has plunged by 66% YoY and by 27% from the previous quarter
The return on equity has dropped by 51% year-on-year and by 21% since the previous quarter
RAPT's ROA is down by 46% YoY and by 19% QoQ

Dividends

What is RAPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RAPT.

Financial health

How did RAPT Therapeutics financials performed over time
RAPT Therapeutics's quick ratio has shrunk by 58% YoY and by 14% QoQ
The current ratio has dropped by 58% year-on-year and by 14% since the previous quarter
The debt is 95% smaller than the equity
RAPT's equity is down by 40% year-on-year and by 15% since the previous quarter
RAPT Therapeutics's debt to equity has increased by 25% QoQ and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.